Trastuzumab elicit adcc that's why none of the her2 tki came close. Similarly rituximab albeit via Other mechanism also os very safe. They are cancer immune therapies that do not induce virulent immune toxicity which is really a red herring. If the target is expressed specifically on tumor target then therapeutic index allows efficacy without toxicity. Sorry for being unclear. Cheers.
News 
Market Data 
Discover 
